Evaluation of checkpoint kinase targeting therapy in acute myeloid leukemia with complex karyotype

Cancer Biology and Therapy

Volumn 13, Issue 5, 2012, Pages 307-313

  Didier, Christine ^c,d   Demur, Cécile ^b   Grimal, Fanny ^a,b   Jullien, Denis ^a,b   Manenti, Stéphane ^c,d   Ducommun, Bernard ^a,b,d  

^a CNRS   (France)

^b TOULOUSE UNIVERSITY HOSPITAL   (France)

^c INSERM   (France)

^d UNIVERSITÉ DE TOULOUSE   (France)

Author keywords

AML; Checkpoint; DNA damage

Indexed keywords

ATM PROTEIN; ATR PROTEIN; AZD 7762; CYTARABINE; ETOPOSIDE; HISTONE H2AX; NOCODAZOLE; PROTEIN SERINE THREONINE KINASE INHIBITOR; UNCLASSIFIED DRUG;

ACUTE GRANULOCYTIC LEUKEMIA; ADULT; AGED; APOPTOSIS; ARTICLE; BLAST CELL; CELL CYCLE G2 PHASE; CELL CYCLE M PHASE; CLINICAL ARTICLE; COLONY FORMING UNIT GM; DNA DAMAGE; DRUG POTENTIATION; GENOMIC INSTABILITY; GENOTOXICITY; HUMAN; HUMAN CELL; KARYOTYPE; LEUKEMIA CELL LINE; LEUKEMIA RELAPSE; MITOSIS; OSTEOSARCOMA CELL;

AGED; APOPTOSIS; CELL CYCLE CHECKPOINTS; CELL LINE, TUMOR; HUMANS; KARYOTYPE; LEUKEMIA, MYELOID, ACUTE; MIDDLE AGED; MOLECULAR TARGETED THERAPY; PROTEIN KINASE INHIBITORS; PROTEIN KINASES; THIOPHENES; UREA;

EID: 84857850947     PISSN: 15384047     EISSN: 15558576     Source Type: Journal    
DOI: 10.4161/cbt.19074     Document Type: Article

References (24)

1. Gorgoulis VG, Vassiliou LV, Karakaidos P, Zacharatos P, Kotsinas A, Liloglou T, et al. Activation of the DNA damage checkpoint and genomic instability in human precancerous lesions. Nature 2005; 434:907-13; http://dx.doi.org/10.1038/nature03485; PMID:15829965.
2. Bartkova J, Horejsi Z, Koed K, Kramer A, Tort F, Zieger K, et al. DNA damage response as a candidate anti-cancer barrier in early human tumorigenesis. Nature 2005; 434:864-70; http://dx.doi.org/10.1038/nature03482; PMID:15829956.
3. Halazonetis TD, Gorgoulis VG, Bartek J. An oncogene-induced DNA damage model for cancer development. Science 2008; 319:1352-5; http://dx.doi. org/10.1126/science.1140735; PMID:18323444.
4. Zhou BB, Anderson HJ, Roberge M. Targeting DNA checkpoint kinases in cancer therapy. Cancer Biol Ther 2003; 2:16-22; PMID:14508077.
5. Bartek J, Lukas J. DNA damage checkpoints: from initiation to recovery or adaptation. Curr Opin Cell Biol 2007; 19:238-45; http://dx.doi.org/10.1016/j. ceb.2007.02.009; PMID:17303408.
6. Zabludoff SD, Deng C, Grondine MR, Sheehy AM, Ashwell S, Caleb BL, et al. AZD7762, a novel checkpoint kinase inhibitor, drives checkpoint abrogation and potentiates DNA-targeted therapies. Mol Cancer Ther 2008; 7:2955-66; http://dx.doi.org/10.1158/1535-7163.MCT-08-0492; PMID:18790776.
7. Mitchell JB, Choudhuri R, Fabre K, Sowers AL, Citrin D, Zabludoff SD, et al. In vitro and in vivo radiation sensitization of human tumor cells by a novel check-point kinase inhibitor, AZD7762. Clin Cancer Res 2010; 16:2076-84; http://dx.doi.org/10.1158/1078-0432.CCR-09-3277; PMID:20233881.
8. Morgan MA, Parsels LA, Zhao L, Parsels JD, Davis MA, Hassan MC, et al. Mechanism of radiosensitization by the Chk1/2 inhibitor AZD7762 involves abrogation of the G2 checkpoint and inhibition of homologous recombinational DNA repair. Cancer Res 2010; 70:4972-81; http://dx.doi.org/10.1158/0008-5472.CAN- 09-3573; PMID:20501833.
9. Sampath D, Cortes J, Estrov Z, Du M, Shi Z, Andreeff M, et al. Pharmacodynamics of cytarabine alone and in combination with 7-hydroxystaurosporine (UCN-01) in AML blasts in vitro and during a clinical trial. Blood 2006; 107:2517-24; http://dx.doi.org/10.1182/blood-2005-08-3351; PMID:16293603.
10. Didier C, Cavelier C, Quaranta M, Galcera MO, Demur C, Laurent G, et al. G2/M checkpoint stringency is a key parameter in the sensitivity of AML cells to genotoxic stress. Oncogene 2008; 27:3811-20; http://dx.doi.org/10.1038/sj.onc. 1211041; PMID:18212737.
11. Cavelier C, Didier C, Prade N, Mansat-De Mas V, Manenti S, Recher C, et al. Constitutive activation of the DNA damage signaling pathway in acute myeloid leukemia with complex karyotype: potential importance for checkpoint targeting therapy. Cancer Res 2009; 69:8652-61; http://dx.doi.org/10.1158/0008-5472.CAN- 09-0939; PMID:19843865.
12. Récher C, Beyne-Rauzy O, Demur C, Chicanne G, Dos Santos C, Mas VM, et al. Antileukemic activity of rapamycin in acute myeloid leukemia. Blood 2005; 105:2527-34; http://dx.doi.org/10.1182/blood-2004-06-2494; PMID:15550488.
13. 2 checkpoint inhibitors and identification of the structurally novel compound isogranulatimide. Cancer Res 1998; 58:5701-6; PMID:9865726.
14. Wagner JM, Karnitz LM. Cisplatin-induced DNA damage activates replication checkpoint signaling components that differentially affect tumor cell survival. Mol Pharmacol 2009; 76:208-14; http://dx.doi. org/10.1124/mol.109.055178; PMID:19403702.
15. Chen CC, Yang CF, Lee KD, You JY, Yu YB, Ho CH, et al. Complex karyotypes confer a poor survival in adult acute myeloid leukemia with unfavorable cytogenetic abnormalities. Cancer Genet Cytogenet 2007; 174:138-46; http://dx.doi.org/10.1016/j.cancergencyto. 2006.12.002; PMID:17452256.
16. Jordan CT, Guzman ML. Mechanisms controlling pathogenesis and survival of leukemic stem cells. Oncogene 2004; 23:7178-87; http://dx.doi. org/10.1038/sj.onc.1207935; PMID:15378078.
17. Haferlach C, Dicker F, Herholz H, Schnittger S, Kern W, Haferlach T. Mutations of the Tp53 gene in acute myeloid leukemia are strongly associated with a complex aberrant karyotype. Leukemia 2008; 22:1539-41; http://dx.doi.org/10.1038/leu.2008.143; PMID:18528419.
18. Scorah J, McGowan CH. Claspin and Chk1 regulate replication fork stability by different mechanisms. Cell Cycle 2009; 8:1036-43; http://dx.doi.org/10.4161/cc.8.7.8040; PMID:19270516.
19. Boles NC, Peddibhotla S, Chen AJ, Goodell MA, Rosen JM. Chk1 haploinsufficiency results in anemia and defective erythropoiesis. PLoS ONE 2010; 5:8581; http://dx.doi.org/10.1371/journal.pone.0008581; PMID:20052416.
20. Ma CX, Janetka JW, Piwnica-Worms H. Death by releasing the breaks: CHK1 inhibitors as cancer therapeutics. Trends Mol Med 2011; 17:88-96; http://dx.doi.org/10.1016/j.molmed.2010.10.009; PMID:21087899.
21. Grimwade D, Walker H, Oliver F, Wheatley K, Harrison C, Harrison G, et al. The importance of diagnostic cytogenetics on outcome in AML: analysis of 1,612 patients entered into the MRC AML 10 trial. The Medical Research Council Adult and Children's Leukaemia Working Parties. Blood 1998; 92:2322-33; PMID:9746770.
22. Schlenk RF, Benner A, Hartmann F, del Valle F, Weber C, Pralle H, et al. Risk-adapted postremission therapy in acute myeloid leukemia: results of the German multicenter AML HD93 treatment trial. Leukemia 2003; 17:1521-8; http://dx.doi.org/10.1038/sj.leu.2403009; PMID:12886238.
23. Jullien D, Bugler B, Dozier C, Cazales M, Ducommun B. Identification of N-terminally truncated stable nuclear isoforms of CDC25B that are specifically involved in G2/M checkpoint recovery. Cancer Res 2011; 71:1968-77; http://dx.doi.org/10.1158/0008-5472.CAN-10-2453; PMID:21363925.
24. Cazales M, Quaranta M, Lobjois V, Jullien D, Al Saati T, Delsol G, et al. A new mitotic-cell specific monoclonal antibody. Cell Cycle 2008; 7:267-8; http://dx.doi. org/10.4161/cc.7.2.5306; PMID:18256524.